OpGen’s subsidiary Curetis receives batch of 10 new C-series Unyvero A30

OpGen reported that its German subsidiary, Curetis GmbH, has received the full set of ten Unyvero A30 C-Series instruments, which have been assembled by its development partner, DMTPe, in Germany. The instruments have successfully passed electrical and functional testing and will allow rapid sample-to-answer molecular testing with numerous chemistries and assay formats. Andreas Boos, CTO of Curetis and program lead of the Unyvero A30 platform project commented: “We are excited to have taken possession of this newest batch of instruments. With all of the improvements made to date, this is now very close to the final release version of the product. We intend to use the A30 C-Series instruments in all further product development and clinical trials as well as regulatory submissions for our application cartridges on the A30 system.” Mr. Boos added that, “all of our ten B-Series instruments have also been upgraded to this latest standard to plan for sufficient A30 instruments to be available for the continued development of our own assays and cartridges in house, and for collaborative projects such as the FIND R&D collaboration which aims to bring an A30 platform and antimicrobial resistance test from blood cultures to low and middle income countries, as well as for other R&D collaboration projects funded by third party partners.”